Catalent

Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.

Harmonizing technological innovation and a platform approach in biomanufacturing can reduce time and cost barriers to produce stable, high-expressing antibody-based therapeutics.

By integrating QbD into the development process, organizations can achieve robust manufacturing processes, regulatory compliance, and commercial success.

Webinar Date/Time: Thu, Oct 31, 2024 11:00 AM EDT

Webinar Date/Time: Wed, Oct 16, 2024 11:00 AM EDT

Implementing automation involves careful optimization and fine-tuning of various parameters to ensure the accurate execution of cell-based potency assays.

Webinar Date/Time: Thu, Apr 25, 2024 11:00 AM EDT

Webinar Date/Time: Wed, May 8, 2024 11:00 AM EDT

Webinar Date/Time: Wed, Feb 28, 2024 11:00 AM EST

Webinar Date/Time: Thu, Dec 14, 2023 11:00 AM EST

Shorten clinical development timeline using novel GPEx® Lightning cell line development technology.

CDMO Catalent’s UpTempo℠ adeno-associated viral (AAV) platform process accelerates time from gene to clinic.

Catalent provides fill/finish services in a range of formats to support clinical and commercial products.

Shorten clinical development timeline using novel GPEx® Lightning technology

Catalent’s UpTempo Virtuoso™ AAV platform accelerates development, delivering clinical material in 9 months.

OneBio® Suite is an integrated solution for biologics development that reduces timelines, risk and complexity.

Catalent provides fill/finish services across a range of product formats from clinical to commercial scale.

Interest in mRNA as a therapeutic modality has exploded since the approval of mRNA-based COVID-19 vaccines.

Perfusion technology is a tool to increase productivity that can be applied at different stages during upstream cell culture for biotherapeutics products. Perfusion allows removal of waste by-products and replenishment of fresh nutrients so that the cells are able to grow and reach higher cell densities and higher productivity. N-1 perfusion, the application of the perfusion technology in the step immediately before the production bioreactor, is a good option for processes that exhibit low productivity. Join Claudia Berdugo, Ph.D., Director of Process Development at Catalent Biologics, for a podcast where she discusses N-1 perfusion and how Catalent Biologics works toward process improvements for each client to enable them to move their pharmaceutical products forward with confidence.

Catalent’s GPEx® Lightning provides next-generation cell line engineering to accelerate development of biologic molecules.

Catalent Cell & Gene Therapy is a full-service partner for plasmid DNA, viral vectors, and autologous and allogeneic cell therapies.

In this podcast, Catalent Biologics regulatory expert, Kelly Davis shares her insights on why companies choose to repurpose drugs, what the main considerations are when doing so, how companies can overcome the challenges they face, and how Catalent supports companies going through this process.

Cell therapy market has been experiencing double digit growth in recent years stemming from the promising success of the first autologous CAR-T products. However, manufacturing these therapies at scale continues to be a challenge. This podcast will focus on the specialized needs of manufacturing cell therapies at scale and how Custom Manufacturing Organizations are stepping in to drive process efficiencies and standardization.

*** Live: Wednesday, November 11, 2020 | 8:30 AM EDT – 4:00 PM EDT *** 2020 Bio/Pharma Virtual Congress: Join Pharmaceutical Technology® and BioPharm International® for this online event that will explore the latest developments in formulation, manufacturing, and innovative drug dosage forms, as well as detailed discussions about crucial topics impacting the industry. ***On demand available after final airing until 11/11/2021***